Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by TITO R MENDOZA and LORETTA A WILLIAMS.
TITO R MENDOZA
Connection Strength
2.338
LORETTA A WILLIAMS
  1. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma. Sci Rep. 2024 06 27; 14(1):14839.
    View in: PubMed
    Score: 0.242
  2. Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID). J Patient Rep Outcomes. 2023 05 26; 7(1):48.
    View in: PubMed
    Score: 0.224
  3. Development and Validation of a Patient-reported Outcome Measure for Gastrointestinal Obstruction in the Setting of Advanced Malignancy. Ann Surg. 2022 12 01; 276(6):e805-e811.
    View in: PubMed
    Score: 0.190
  4. The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. J Patient Rep Outcomes. 2020 Feb 19; 4(1):15.
    View in: PubMed
    Score: 0.179
  5. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). J Patient Rep Outcomes. 2019 Jun 17; 3(1):34.
    View in: PubMed
    Score: 0.171
  6. Assessment of baseline symptom burden in treatment-na?ve patients with lung cancer: an observational study. Support Care Cancer. 2019 Sep; 27(9):3439-3447.
    View in: PubMed
    Score: 0.166
  7. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Qual Life Res. 2018 Dec; 27(12):3229-3241.
    View in: PubMed
    Score: 0.162
  8. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer. 2019 Mar; 27(3):1021-1028.
    View in: PubMed
    Score: 0.161
  9. Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain. 2015 Oct; 16(10):1032-43.
    View in: PubMed
    Score: 0.130
  10. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7.
    View in: PubMed
    Score: 0.113
  11. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013 Feb 05; 6:13.
    View in: PubMed
    Score: 0.110
  12. Trans-pacific multicenter collaborative study of minimally invasive proximal versus total gastrectomy for proximal gastric and gastroesophageal junction cancers. BMC Surg. 2023 Sep 01; 23(1):262.
    View in: PubMed
    Score: 0.057
  13. Symptom Burden in Patients with Malignant Bowel Obstruction Treated With or Without Surgery. J Am Coll Surg. 2023 03 01; 236(3):514-522.
    View in: PubMed
    Score: 0.054
  14. Identification of Breast Cancer Survivors With High Symptom Burden. Cancer Nurs. 2022 Jul-Aug 01; 45(4):253-261.
    View in: PubMed
    Score: 0.051
  15. Percutaneous Cordotomy for Pain Palliation in Advanced Cancer: A Randomized Clinical Trial Study Protocol. Neurosurgery. 2020 08 01; 87(2):394-402.
    View in: PubMed
    Score: 0.046
  16. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 10; 16(10):e1151-e1160.
    View in: PubMed
    Score: 0.046
  17. Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35.
    View in: PubMed
    Score: 0.034
  18. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.
    View in: PubMed
    Score: 0.033
  19. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46.
    View in: PubMed
    Score: 0.031
  20. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41.
    View in: PubMed
    Score: 0.031
  21. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.
    View in: PubMed
    Score: 0.029
  22. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
    View in: PubMed
    Score: 0.028
  23. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1531-40.
    View in: PubMed
    Score: 0.028
  24. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010 Apr 15; 116(8):2053-63.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.